A biomimetic Trojan Horse inspired exosome-hydrogel-bone scaffold nested cascade delivery system: Modulating the "Don't Eat Me" signal for synergistic intracellular-targeted acid-responsive antibacterial therapy and bone regeneration
Infectious bone defects caused by bone tuberculosis remain a challenging clinical problem due to the dual predicaments of persistent intracellular survival of pathogens and inefficient bone regeneration. This study constructed an exosome-hydrogel-bone scaffold system (antiMExo-RFT-SAH@HA/β-TCP) (antiMExo, anti-CD47 antibody-modified Macrophage Exosomes; SAH, Sodium alginate hydrogel; RFT, rifapentine; HA/β-TCP, Hydroxyapatite/β-tricalcium phosphate)based on a biomimetic Trojan Horse strategy, which enables the synergistic effect of targeted antibacterial therapy and potent bone regeneration. Exosomes were modified with anti-CD47 antibody to block the CD47-SIRPα (Signal Regulatory Protein α) "Don't Eat Me" signal axis, reconstructing exosomes into biomimetic Trojan Horses that can evade immune surveillance, thereby achieving targeted endocytosis by MTB (Mycobacterium tuberculosis)-infected macrophages. A four-level nested cascade release mechanism (HA/β-TCP→SAH→MExo→RFT) was then integrated to maintain sustained antibacterial efficacy through spatiotemporally controlled drug delivery, overcoming the limitations of poor penetration and short retention time in traditional treatments. Intracellularly, a “Dual-Track Killing” mechanism was triggered: direct bactericidal effect of RFT and clearance of bacterial nests by reactive oxygen species-mediated macrophage apoptosis, synergistically eliminating intracellular MTB. Meanwhile, the synergistic osteogenic effect of exosomes and scaffolds, through coordinated regulation at structural, tissue, and molecular levels, achieved stepwise bone regeneration characterized by "initiation at 1 week, rapid osteogenesis at 3 weeks, and maturation at 6 weeks". This multifunctional platform provides an innovative paradigm for precise treatment and functional repair of tuberculous bone defects. Its integration of targeted delivery, sustained efficacy, and tissue regeneration holds promise for promoting clinical translation in the treatment of complex infectious bone diseases.